The safety and efficacy of febuxostat in patients with stage 4-5 chronic kidney disease (CKD) are still unclear owing to a lack of studies in these patients. Therefore, we aimed to evaluate the effect of febuxostat on renal function, general safety, and efficacy in gout patients with stage 4-5 CKD. Among 739 patients who had been administered febuxostat from May 2012 to December 2016 at a single hospital in Korea, 370 patients who had been monitored for 1 year were analyzed. Serum uric acid levels and estimated glomerular filtration rate (eGFR) of patients with gouty arthritis were collected at baseline and 1 year after febuxostat administration. Among the 370 patients, 280 patients were stage 1-3 CKD, 63 patients were stage 4-5 CKD, and 27 patients were on dialysis. The eGFR of 63 patients with stage 4-5 CKD, excluding dialysis patients, was 19.84 ± 7.08 mL/min/1.73 m2 when they began to take febuxostat and 23.49 ± 16.67 mL/min/1.73 m2 after 12 months (p = 0.13). The urate-lowering effect after 12 months of febuxostat medication showed statistical significance (8.96 ± 2.31 mg/dL at baseline and 4.88 ± 1.68 mg/dL after 12 months, p 0.01). The difference in incidence of adverse events among patients with stage 1-3 CKD, those with stage 4-5 CKD, and those on dialysis was not significant. Febuxostat demonstrated renal safety and good urate-lowering efficacy in gout patients with stage 4-5 CKD, who are not yet on dialysis.
展开▼
机译：由于这些患者的研究缺乏研究，Febuxostat在阶段4-5阶段慢性肾病（CKD）中的安全性和疗效仍然不清楚。因此，我们旨在评估Febuxostat对痛风患者4-5 CKD患者肾功能，一般安全性和疗效的影响。在2012年5月至2016年5月在韩国的一家医院进行的739名曾经在2016年到2016年12月，分析了370名被监测患者1年。在基线和2月份后1年内收集痛风性关节炎患者的血清尿酸水平和估计的肾小球过滤速率（EGFR）。在370名患者中，280名患者是1-3次CKD，63名患者是4-5℃，27例患者透析。 43例患有63例患者的EGFR患者，不包括透析患者，19.84±7.08 ml / min / 1.73m2，当时12个月后23.49±16.67 ml / min / 1.73m2（p = 0.13） 。 2个月后2个月后的口腔效果显示出统计学意义（基线8.96±2.31 mg / dl，12个月后4.88±1.68 mg / dl，P <0.01）。阶段1-3 CKD患者的不良事件发生率的差异，患有阶段4-5 CKD，透析患者不显着。 Febuxostat表现出肾脏安全性和降低痛风患者的肾脏安全性和良好的尿液疗效，尚未在透析中尚未进行透析。
展开▼
